Roztroušená skleróza – odhalené tajemství imunity
Authors:
I. S. Barac 1; V. Văcăraș 1; A. Cozma 2; L. M. Procopciuc 3
Authors‘ workplace:
Department of Clinical Neurosciences, „Iuliu Haţieganu“ University of Medicine and Pharmacy, Cluj-Napoca, Romania
1; Department of Internal Medicine, „Iuliu Haţieganu“ University of Medicine and Pharmacy, Cluj-Napoca, Romania
2; Department of Biochimistry, „Iuliu Haţieganu“ University of Medicine and Pharmacy Cluj-Napoca, Romania
3
Published in:
Cesk Slov Neurol N 2020; 83/116(4): 368-374
Category:
Review Article
doi:
https://doi.org/10.14735/amcsnn2020368
Overview
Roztroušená skleróza je porucha CNS, která u mladých dospělých po celém světě vede k závažné invaliditě a kognitivním poruchám, což má významný emoční a socioekonomický dopad. Je stále více důkazů o tom, že na iniciaci a progresi tohoto onemocnění se podílí mechanizmy související s imunitou. S významným objevem glymfatického systému a meningeálních lymfatických cév, které jsou nezbytné pro odvádění metabolického odpadu z intersticia, došlo v nejnovějších studiích k předefinování jedinečného konceptu chápání mozku jako imunologicky privilegovaného orgánu. V tomto přehledném referátu se stručně věnujeme složitému spojení mezi CNS a periferním imunitním systémem, kdy buňky imunitního systému přestupují hematoencefalickou bariéru a jsou mediátory rozvoje tohoto onemocnění a rovněž mají přístup k zvláštnímu systému lymfatické drenáže mozku s podílem na etiologii RS. Imunitní systém, který má při poškození neuronů a regeneraci tkání kontrastní role, se tak v úsilí o nalezení vhodné léčby stává váženým partnerem.
Klíčová slova:
roztroušená skleróza – vrozená imunita – získaná imunita – glymfatický systém
Sources
1. Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol 2014; 122: 15–58. doi: 10.1016/B978-0-444-52001-2.00002-9.
2. Wang K, Song F, Fernandez-Escobar A et al. The properties of cytokines in multiple sclerosis: pros and cons. Am J Med Sci 2018; 356 (6): 552–560. doi: 10.1016/j.amjms.2018.08.018.
3. Louveau A, Da Mesquita S, Kipnis J. Lymphatics in neurological disorders: A neuro-lympho-vascular component of multiple sclerosis and Alzheimer’s disease? Neuron 2016; 91: 957–73. doi: 10.1016/j.neuron.2016.08.027.
4. Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science 2016; 353 (6301): 766–771. doi: 10.1126/science.aag2 638.
5. Vasileiadis GK, Dardiotis E, Mavropoulos A et al. Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? Autoimmun Highlights 2018; 9 (1): 9. doi: 10.1007/s13317-018-0109-x.
6. Ponath G, Park C, Pitt D. The role of astrocytes in multiple sclerosis. Front Immunol 2018; 9: 217. doi: 10.3389/fimmu.2018.00217.
7. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J 2017; 19 (1): 1–10. doi: 10.22074/cellj.2016.4867.
8. Grigoriadis N, van Pesch V. A basic overview of multiple sclerosis immunopathology. Eur J Neurol 2015; 22 (Suppl 2): 3–13. doi: 10.1111/ene.12798.
9. Sevim S. Relapses in multiple sclerosis: definition, pathophysiology, features, imitators, and treatment. Turkish J Neurol 2016; 22 (3): 99–108. doi: 10.4274/tnd.75318.
10. Salvetti M, Landsman D, Schwarz-Lam P et al. Progressive MS: from pathophysiology to drug discovery. Mult Scler 2015; 21 (11): 1376–1384. doi: 10.1177/ 1352458515603802.
11. Trojano M, Avolio C. Environmental factors and their regulation of immunity in multiple sclerosis. Transl Neuroimmunol Mult Scler From Dis Mech to Clin Appl 2016; 324: 100–111. doi: 10.1016/B978-0-12-801914-6.00008-8.
12. Yadav SK, Mindur JE, Ito K et al. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 2015; 28 (3): 206–219. doi: 10.1097/WCO.000000000000 0205.
13. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 2015; 14 (4): 406–419. doi: 10.1016/S1474-4422 (14) 70305-9.
14. Hossain MJ, Tanasescu R, Gran B. Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2. J Neuroimmunol 2017; 304: 11–20. doi: 10.1016/j.jneuroim.2016.12.004.
15. Fraussen J, de Bock L, Somers V. B cells and antibodies in progressive multiple sclerosis: contribution to neurodegeneration and progression. Autoimmun Rev 2016; 15 (9): 896–899. doi: 10.1016/j.autrev.2016.07. 008.
16. Podbielska M, O’Keeffe J, Hogan EL. Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration. J Neurol Sci 2018; 385: 198–214. doi: 10.1016/j.jns.2017.12.022.
17. Herz J, Filiano AJ, Smith A et al. Myeloid cells in the central nervous system. Immunity 2017; 46 (6): 943–956. doi: 10.1016/j.immuni.2017.06.007.
18. Perlmutter D. The role of inflammation in neurodegenerative disorders. [online]. Available from URL: https: //www.a4m.com/assets/pdf/bookstore/aamt_vol7_30_perlmutter.pdf.
19. Hernández-Pedro NY, Espinosa-Ramirez G, De La Cruz VP et al. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol 2013; 2013: 413465. doi: 10.1155/2013/413465.
20. Stephenson J, Nutma E, van der Valk P et al. Inflammation in CNS neurodegenerative diseases. Immunology 2018; 154 (2): 204–219. doi: 10.1111/imm.12922.
21. McKeon A. Clinical neuroimmunology multiple sclerosis and related disorders. New York: Humana Press 2012.
22. Tuzun E. Immunopathological factors associated with disability in multiple sclerosis. Arch Neuropsychiatry 2018; 55 (Suppl 1): S26–S30. doi: 10.29399/npa.23 303.
23. Durrenberger PF, Ettore A, Kamel F et al. Innate immunity in multiple sclerosis white matter lesions: Expression of natural cytotoxicity triggering receptor 1 (NCR1). J Neuroinflammation 2012: 9: 1. doi: 10.1186/1742-2094-9-1.
24. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221 (1–2): 7–14. doi: 10.1016/j.jneuroim.2009.10.015.
25. Hosseini A, Masjedi A, Baradaran B et al. Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis. J Cell Physiol 2019; 234 (7): 9943–9955. doi: 10.1002/jcp.27930.
26. Sospedra M, Martin R. Immunology of multiple sclerosis. Semin Neurol 2016; 36 (2): 115–127. doi: 10.1055/s-0036-1579739.
27. Woodberry T, Bouffler S, Wilson A et al. The emerging role of neutrophil granulocytes in multiple sclerosis. J Clin Med 2018; 7 (12): 511. doi: 10.3390/jcm7120511.
28. Hänninen A. Infections in MS: An innate immunity perspective. Acta Neurol Scand 2017; 136 (Suppl 201): 10–14. doi: 10.1111/ane.12838.
29. Valente LA, Begg LR, Filiano AJ. Updating neuroimmune targets in central nervous system dysfunction. Trends Pharmacol Sci 2019; 40 (7): 482–494. doi: 10.1016/j.tips.2019.04.013.
30. Naegele M, Martin R. The good and the bad of neuroinflammation in multiple sclerosis. Handb Clin Neurol 2014; 122: 59–87. doi: 10.1016/B978-0-444-52001-2.00 003-0.
31. Adamczyk-Sowa M, Medrek A, Madej P et al. Does the gut microbiota influence immunity and inflammation in multiple sclerosis pathophysiology? J Immunol Res 2017; 2017: 7904821. doi: 10.1155/2017/7904821.
32. Lubetzki C, Stankoff B. Demyelination in multiple sclerosis. Handb Clin Neurol 2014; 122: 89–99. doi: 10.1016/B978-0-444-52001-2.00004-2.
33. Chihara N. Dysregulated T cells in multiple sclerosis. Clin Exp Neuroimmunol 2018; 9 (Suppl 1): 20–29. doi: 10.1111/cen3.12438.
34. Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 2005; 6 (1): 17–21. doi: 10.1038/ni1153.
35. Kim JK, Shin YJ, Ha LJ et al. Unraveling the mechanobiology of the immune system. Adv Healthc Mater 2019; 8 (4): e1801332. doi: 10.1002/adhm.201801332.
36. Merlo LMF, Mandik-Nayak L. Adaptive immunity: B cells and antibodies. 2nd ed. Amsterdam: Elsevier 2013.
37. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6 (2): 107–116. doi: 10.1038/nri1780.
38. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol 2018; 19 (7): 696–707. doi: 10.1038/s41590-018-0135-x.
39. Palanichamy A, Apeltsin L, Kuo TC et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 2014; 6 (248): 248ra106. doi: 10.1126/scitranslmed.3008930.
40. Wildner P, Selmaj KW. Multiple sclerosis: skin-induced antigen-specific immune tolerance. J Neuroimmunol 2017; 311: 49–58. doi: 10.1016/j.jneuroim.2017.08.001.
41. Funaro MG, Messina M, Shabbir M et al. The role of B cells in multiple sclerosis: more than antibodies. Discov Med 2016; 22 (122): 251–255.
42. Dhaeze T, Peelen E, Hombrouck A et al. Circulating follicular regulatory T cells are defective in multiple sclerosis. J Immunol 2015; 195 (3): 832–840. doi: 10.4049/jimmunol.1500759.
43. Lazibat I, Majdak MR, Županić S. Multiple sclerosis: new aspects of immunopathogenesis. Acta Clin Croat 2018; 57 (2): 352–361. doi: 10.20471/acc.2018.57.02.17.
44. Luckheeram RV, Zhou R, Verma AD et al. CD4 +T cells: differentiation and functions. Clin Dev Immunol 2012; 2012: 925135. doi: 10.1155/2012/925135.
45. Hendricks DW, Fink PJ. Recent thymic emigrants are biased against the T-helper type 1 and toward the T-helper type 2 effector lineage. Blood 2011; 117 (4): 1239–1249. doi: 10.1182/blood-2010-07-299 263.
46. Manglani M, McGavern DB. New advances in CNS immunity against viral infection. Curr Opin Virol 2018; 28: 116–126. doi: 10.1016/j.coviro.2017.12. 003.
47. Engelhardt B, Carare RO, Bechmann I et al. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol 2016; 132 (3): 317–338. doi: 10.1007/s00401-016-1606-5.
48. Lossius A, Johansen JN, Vartdal F et al. High-throughput sequencing of immune repertoires in multiple sclerosis. Ann Clin Transl Neurol 2016; 3 (4): 295–306. doi: 10.1002/acn3.295.
49. Tamura R, Yoshida K, Toda M. Current understanding of lymphatic vessels in the central nervous system. Neurosurg Rev 2020; 43 (4): 1055–1064. doi: 10.1007/s10143-019-01133-0.
50. Al-Kofahi M, Yun JW, Minagar A et al. Anatomy and roles of lymphatics in inflammatory diseases. Anat Roles Lymphat Inflamm Dis 2017; 8 (3): 199–214. doi: 10.1111/cen3.12400.
51. Simon MJ, Iliff JJ. Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochim Biophys Acta 2016; 1862 (3): 442–451. doi: 10.1016/j.bbadis.2015.10.014.
52. Peruzzotti-Jametti L, Pluchino S. Targeting mitochondrial metabolism in neuroinflammation: towards a therapy for progressive multiple sclerosis. Trends Mol Med 2018; 24 (10): 838–855. doi: 10.1016/j.molmed.2018.07.007.
53. Plog BA, Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol Mech Dis 2018; 13: 379–394. doi: 10.1146/annurev-pathol-051217-111018.
54. Weller RO, Carare RO. Lymphatic drainage of the CNS and its role in neuroinflammation and neurodegenerative disease. Amsterdam: Elsevier 2018.
55. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol 2018; 17 (11): 1016–1024. doi: 10.1016/S1474-4422 (18) 30318-1.
56. Zamboni P. The Contribution of extra cranial venous drainage to neuro-inflammation in multiple sclerosis. Amsterdam: Elsevier 2018.
57. Sati P, Oh J, Todd Constable R et al. The central vein sign and its clinical evaluation for the diag- nosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016; 12 (12): 714–722. doi: 10.1038/nrneurol.2016.166.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
![Issue 4](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/397179c8f92e6e77dfb4221440fc6232.jpeg)
2020 Issue 4
Most read in this issue
- Je jasné, kdy operovat výhřez bederní meziobratlové ploténky?
- CGRP monoklonální protilátky v léčbě migrény – indikační kritéria a terapeutická doporučení pro Českou republiku
- Současná diagnostika sekundárně progresivní formy roztroušené sklerózy a léčba siponimodem
- Dropped head syndrom u pacientky s progredující bulbární paralýzou